Article

Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Division of Geriatric Psychiatry, Columbia University, New York, USA.
Journal of Geriatric Psychiatry and Neurology (Impact Factor: 1.63). 09/2010; 23(3):185-98. DOI: 10.1177/0891988710363715
Source: PubMed

ABSTRACT Amyloid load in the brain using Pittsburgh compound B ((11)C-PIB) positron emission tomography (PET) and cerebral glucose metabolism using fluorodeoxyglucose ((18)F-FDG) PET were evaluated in patients with mild Alzheimer disease (AD, n = 18), mild cognitive impairment (MCI, n = 24), and controls (CTR, n = 18). ( 11)C-PIB binding potential (BP(ND)) was higher in prefrontal cortex, cingulate, parietal cortex, and precuneus in AD compared to CTR or MCI and in prefrontal cortex for MCI compared to CTR. For (18)F-FDG, regional cerebral metabolic rate for glucose (rCMRGlu) was decreased in precuneus and parietal cortex in AD compared to CTR and MCI, with no MCI-CTR differences. For the AD-CTR comparison, precuneus BP(ND) area under the receiver operating characteristic (ROC) curve (AUC) was 0.938 and parietal cortex rCMRGlu AUC was 0.915; for the combination, AUC was 0.989. ( 11)C-PIB PET BP(ND) clearly distinguished diagnostic groups and combined with (18)F-FDG PET rCMRGlu, this effect was stronger. These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies.

0 Followers
 · 
170 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PET based tools can improve the early diagnosis of Alzheimer's disease (AD) and differential diagnosis of dementia. The importance of identifying individuals at risk of developing dementia among people with subjective cognitive complaints or mild cognitive impairment has clinical, social, and therapeutic implications. Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement. As a consequence, the PET tools have been recognized to be of crucial value in the recent guidelines for the early diagnosis of AD and other dementia conditions. The references based recommendations, however, include large PET imaging literature based on visual methods that greatly reduces sensitivity and specificity and lacks a clear cut-off between normal and pathological findings. PET imaging can be assessed using parametric or voxel-wise analyses by comparing the subject's scan with a normative data set, significantly increasing the diagnostic accuracy. This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD. This allowed a meta-analysis and GRADE analysis revealing high values for PET imaging that might be useful in considering recommendations.
    03/2014; 2014:785039. DOI:10.1155/2014/785039
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A pharmaceutical intervention that has received great attention in recent years for treating Alzheimer's disease (AD) is the use of antibodies targeting amyloid beta (Aβ) in the brain, as the formation of Aβ plaques is considered as being the driving force for the development and progression of AD. Recently, a Phase III trial in patients with mild-to-moderate AD has provided ambivalent evidence for the efficacy of this intervention. In this trial, the intravenous administration of bapineuzumab, a monoclonal antibody targeting Aβ in the brain, for 78 weeks led to a reduction of cerebrospinal fluid levels of phosphorylated tau and evidence for lower Aβ accumulation in the brain of AD patients who carried APOE ε4. However, this treatment did not improve clinical outcomes (e.g. the rate of cognitive decline) in these patients. Similar null results with respect to the rate of cognitive decline were found in a separate Phase III clinical trial after treatment with solanezumab. Based on these findings, one conclusion could be that antibodies targeting Aβ in the brain may unfold their highest efficacy when given before the development of clinical AD symptoms, i.e. during a period where neurodegeneration but not cognitive loss represents the major pathology. Another conclusion could be that antibody-based pharmaceutical interventions may fail to slow the progress of cognitive loss in patients who have AD because of their solely pharmaceutical therapeutic approach. Leisure activities that require patients' mental and physical abilities (e.g. exercise) are associated with a reduced risk of developing dementia. In the same manner, they may help to curb the progress of this devastating disease. Thus, combining the use of antibodies targeting Aβ with therapeutic strategies that require patients' mental and physical abilities might help tackle the neurodegenerative dynamics and cognitive loss both in patients with AD, and its prodromal state, mild cognitive impairment.
    Experimental Gerontology 09/2014; 57:104-6.. DOI:10.1016/j.exger.2014.05.002 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify the optimal time window for capturing perfusion information from early C-11-PIB imaging frames (perfusion PIB, C-11-pPIB) and to compare the performance of F-18-FDG PET and "dual biomarker" C-11-PIB PET [C-11-pPIB and amyloid PIB (C-11-aPIB)] for classification of AD, MCI and CN subjects. Forty subjects (14 CN, 12 MCI and 14 AD patients) underwent F-18-FDG and C-11-PIB PET studies. Pearson correlation between the F-18-FDG image and sum of early C-11-PIB frames was maximised to identify the optimal time window for C-11-pPIB. The classification power of imaging parameters was evaluated with a leave-one-out validation. A 7-min time window yielded the highest correlation between F-18-FDG and C-11-pPIB. C-11-pPIB and F-18-FDG images shared a similar radioactive distribution pattern. F-18-FDG performed better than C-11-pPIB for the classification of both AD vs. CN and MCI vs. CN. C-11-pPIB + C-11-aPIB and F-18-FDG + C-11-aPIB yielded the highest classification accuracy for the classification of AD vs. CN, and F-18-FDG + C-11-aPIB had the best classification performance for the classification of MCI vs. CN. C-pPIB could serve as a useful biomarker of rCBF for measuring neural activity and improve the diagnostic power of PET for AD in conjunction with C-11-aPIB. F-18-FDG and C-11-PIB dual-tracer PET examination could better detect MCI. aEuro cent Dual-tracer PET examination provides neurofunctional and neuropathological information for AD diagnosis. aEuro cent The identified optimal 11C-pPIB time frames had highest correlation with 18F-FDG. aEuro cent 11C-pPIB images shared a similar radioactive distribution pattern with 18F-FDG images. aEuro cent 11C-pPIB can provide neurofunctional information. aEuro cent Dual-tracer PET examination could better detect MCI.
    European Radiology 08/2014; 24(11). DOI:10.1007/s00330-014-3311-x · 4.34 Impact Factor

Full-text (2 Sources)

Download
50 Downloads
Available from
Jun 1, 2014